Special Issue

The Past, Present, and Future of Pulmonary Hypertension: Pathophysiology and Treatment Prospects

Message from the Guest Editors

Pulmonary hypertension (PH) remains a complex and evolving disorder involving the pulmonary vasculature. This Special Issue explores the historical milestones that shaped our foundational understanding of PH. recent advances in diagnostic and therapeutic strategies, and future directions in treatment approaches. This collection aims to provide a comprehensive overview of the changing landscape of PH. Topics may include translational genetics and metabolomics in PH physiology, current challenges in classification and risk stratification, and emerging therapies-from novel drug targets to precision medicine approaches. We invite contributions that reflect the depth of PH research, with the goal of inspiring continued innovation in improving outcomes for patients with this life-threatening condition.

Guest Editors

Dr. Roxana Sulica

Department of Medicine, Pulmonary Critical Care and Sleep Division, New York University Grossman School of Medicine, New York University Langone Health, New York, NY 10016, USA

Dr. Himanshu Deshwal

Pulmonary Hypertension Clinic, Section of Pulmonary, Sleep and Critical Care Medicine, Department of Medicine, West Virginia University School of Medicine, Morgantown, WV 26505, USA

Deadline for manuscript submissions

31 March 2026



Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/248558

Journal of Cardiovascular Development and Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcdd@mdpi.com

mdpi.com/journal/ jcdd





Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease (JCDD*, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand National Heart & Lung Institute, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).